Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. News
Sep 11, 2023 - globenewswire.com
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
Aug 7, 2023 - businesswire.com
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
Magenta Therapeutics, Inc. Quantitative Score
About Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Magenta Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Magenta Therapeutics, Inc. Financials
Table Compare
Compare MGTA metrics with: | |||
|---|---|---|---|
Earnings & Growth | MGTA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MGTA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MGTA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MGTA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Magenta Therapeutics, Inc. Income
Magenta Therapeutics, Inc. Balance Sheet
Magenta Therapeutics, Inc. Cash Flow
Magenta Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Magenta Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Jason Gardner DPHIL, Ph.D. | Co-Founder, Chief Executive Officer, Pres & Director |
| Mr. Stephen F. Mahoney J.D., MBA | Pres, Chief Financial & Operating Officer and Treasurer |
| Dr. Lisa M. Olson Ph.D. | Head of Research & Chief Scientific Officer |
| Mr. David Wayne Nichols | Chief Technical Officer |
| Lyndsey Scull | Director of Corporation Communications |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Jason Gardner DPHIL, Ph.D. | Co-Founder, Chief Executive Officer, Pres & Director | 1972 | 850.45K | |
| Mr. Stephen F. Mahoney J.D., MBA | Pres, Chief Financial & Operating Officer and Treasurer | Male | 1972 | 637.21K |
| Dr. Lisa M. Olson Ph.D. | Head of Research & Chief Scientific Officer | 1960 | 609.88K | |
| Mr. David Wayne Nichols | Chief Technical Officer | Male | 1964 | 388.92K |
| Lyndsey Scull | Director of Corporation Communications | -- |
Magenta Therapeutics, Inc. Insider Trades
| Date | 29 Sep |
| Name | Fairmount Funds Management LLC |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 24670 |
| Date | 26 Sep |
| Name | Fairmount Funds Management LLC |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 30000 |
| Date | 21 Sep |
| Name | Randhawa Simrat |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2000 |
| Date | 22 Sep |
| Name | Randhawa Simrat |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 2000 |
| Date | 19 Sep |
| Name | Fairmount Funds Management LLC |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 30000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 29 Sep | Fairmount Funds Management LLC | Director, 10 percent owner | Acquired | P-Purchase | 24670 |
| 26 Sep | Fairmount Funds Management LLC | Director, 10 percent owner | Acquired | P-Purchase | 30000 |
| 21 Sep | Randhawa Simrat | Chief Medical Officer | Acquired | P-Purchase | 2000 |
| 22 Sep | Randhawa Simrat | Chief Medical Officer | Acquired | P-Purchase | 2000 |
| 19 Sep | Fairmount Funds Management LLC | Director, 10 percent owner | Acquired | P-Purchase | 30000 |